Allergic Reactions at Enzyme Replacement Therapy in Children with Mucopolysaccharidosis Type II
Julia G. Levina,
Nato D. Vashakmadze,
Leyla S. Namazova-Baranova,
Elena A. Vishneva,
Natalia V. Zhurkova,
Kamilla E. Efendieva,
Anna A. Alekseeva,
Vera G. Kalugina https://doi.org/10.15690/vsp.v20i6S.2372
Abstract
Mucopolysaccharidosis type II (MPS II; Hunter syndrome) is rare hereditary disease caused by changes in the IDS gene and associated deficiency of lysosomal enzyme iduronate-2-sulfatase (I2S). The main treatment scheme for children with MPS II is enzyme replacement therapy (ERT) with recombinant human I2S. The major issue of ERT is development of allergic (sometimes up to severe anaphylaxis) reactions to recombinant enzymes. The article covers features of infusion-related reactions to ERT, it describes pathogenesis, diagnostic criteria management algorithm of anaphylaxis. Whereas, there is the need of further studies on allergic infusion-related reactions to ERT in children.
About the Authors
Julia G. Levina
Research Institute of Pediatrics and Children’s Health in “Central Clinical Hospital of the Russian Academy of Sciences”; Pirogov Russian National Research Medical University
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Julia G. Levina — lecturing for pharmaceutical company Nanolek.
Nato D. Vashakmadze
Research Institute of Pediatrics and Children’s Health in “Central Clinical Hospital of the Russian Academy of Sciences”; Pirogov Russian National Research Medical University
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Nato D. Vashakmadze — lecturing for pharmaceutical companies Taleda, Sanofi, Biomarin, Nakolek.
Leyla S. Namazova-Baranova
Research Institute of Pediatrics and Children’s Health in “Central Clinical Hospital of the Russian Academy of Sciences”; Pirogov Russian National Research Medical University; Belgorod State National Research University
Russian Federation
Disclosure of interest:
Russian Federation
Moscow; Belgorod
Disclosure of interest:
Leyla S. Namazova-Baranova — receiving research grants and fees for scientific counseling and lecturing from pharmaceutical companies “MSD Pharmaceuticals”, “FORT”, Shire Biothech Rus LLC, Pfizer Innovations LLC, Sanofi Aventis Group LLC, AbbVie, Pierre Fabre.
Elena A. Vishneva
Research Institute of Pediatrics and Children’s Health in “Central Clinical Hospital of the Russian Academy of Sciences”; Pirogov Russian National Research Medical University
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
The other contributors confirmed the absence of a reportable conflict of interests.
Natalia V. Zhurkova
Research Institute of Pediatrics and Children’s Health in “Central Clinical Hospital of the Russian Academy of Sciences”; Medical Genetic Research Center named after N.P. Bochkov
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Natalia V. Zhurkova — lecturing for pharmaceutical companies Taleda, Sanofi, Biomarin, Nakolek.
Kamilla E. Efendieva
Research Institute of Pediatrics and Children’s Health in “Central Clinical Hospital of the Russian Academy of Sciences”; Pirogov Russian National Research Medical University
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
The other contributors confirmed the absence of a reportable conflict of interests.
Anna A. Alekseeva
Research Institute of Pediatrics and Children’s Health in “Central Clinical Hospital of the Russian Academy of Sciences”
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
The other contributors confirmed the absence of a reportable conflict of interests.
Vera G. Kalugina
Research Institute of Pediatrics and Children’s Health in “Central Clinical Hospital of the Russian Academy of Sciences”
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
The other contributors confirmed the absence of a reportable conflict of interests.
References
1. Sestito S, Ceravolo F, Grisolia M, et al. Profile of idursulfase for the treatment of Hunter syndrome. Research and Reports in Endocrine Disorders. 2015;5:79–90. doi: 10.2147/RRED.S64347
2. Muenzer J, Wraith JE, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med. 2006;8(8):465–473. doi: 10.1097/01.gim.0000232477.37660.fb
3. Sohn YB, Cho SY, Park SW, et al. Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome). Orphanet J Rare Dis. 2013;8:42. doi: 10.1186/1750-1172-8-42
4. Mukopolisakharidoz tip II: Clinical guidelines. Union of Pediatricians of Russia; Association of Medical Geneticists. Ministry of Health of the Russian Federation; 2021. 79 p. (In Russ). Доступно по: https://cr.minzdrav.gov.ru/recomend/392_2. Ссылка активна на 11.12.2021.
5. Kim C, Seo J, Chung Y, et al. Comparative study of idursulfase beta and idursulfase in vitro and in vivo. J Hum Genet. 2017;62(2): 167–174. doi: 10.1038/jhg.2016.133
6. Miebach E. Management of infusion-related reactions to enzyme replacement therapy in a cohort of patients with mucopolysaccharidosis disorders. Int J Clin Pharmacol Ther. 2009; 47 Suppl 1:S100–S106. doi: 10.5414/cpp47100
7. Burton BK, Whiteman DA. Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS). Mol Genet Metab. 2011;103(2):113–120. doi: 10.1016/j.ymgme.2011.02.018
8. Brooks DA, Kakavanos R, Hopwood JJ. Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder. Trends Mol Med. 2003;9(10):450–453. doi: 10.1016/j.molmed.2003.08.004
9. Demoly P, Adkinson NF, Brockow K, et al. International Consensus on drug allergy. Allergy. 2014;69(4):420–437. doi: 10.1111/all.12350
10. Rasheed S, Nelson-Rees WA, Toth EM, et al. Characterization of a newly derived human sarcoma cell line (HT-1080). Cancer. 1974;33(4):1027–1033. doi: 10.1002/1097-0142(197404)33:4<1027::aid-cncr2820330419>3.0.co;2-z
11. Lai T, Yang Y, Ng SK. Advances in Mammalian cell line development technologies for recombinant protein production. Pharmaceuticals (Basel). 2013;6(5):579–603. doi: 10.3390/ph60505799
12. Vojta A, Samaržija I, Bočkor L, Zoldoš V. Glyco-genes change expression in cancer through aberrant methylation. Biochim Biophys Acta. 2016;1860(8):1776–1785. doi: 10.1016/j.bbagen.2016.01.002
13. D’Avanzo F, Rigon L, Zanetti A, Tomanin R. Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment. Int J Mol Sci. 2020;21(4):1258. doi: 10.3390/ijms21041258
14. Chung YK, Sohn YB, Sohn JM, et al. A biochemical and physicochemical comparison of two recombinant enzymes used for enzyme replacement therapies of hunter syndrome. Glycoconj J. 2014;31(4):309–315. doi: 10.1007/s10719-014-9523-0
15. Ngu LH, Ong Peitee W, Leong HY, Chew HB. Case report of treatment experience with idursulfase beta (Hunterase) in an adolescent patient with MPS II. Mol Genet Metab Rep. 2017;12: 28–32. doi: 10.1016/j.ymgmr.2017.05.002
16. Kim J, Park MR, Kim DS, et al. IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome. Allergy. 2013;68(6):796–802. doi: 10.1111/all.12155
17. Okuyama T, Tanaka A, Suzuki Y, et al. Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccha ridosis II, MPS II). Mol Genet Metab. 2010;99(1):18–25. doi: 10.1016/j.ymgme.2009.08.006
18. Kraft S, Kinet JP. New developments in FcepsilonRI regulation, function and inhibition. Nat Rev Immunol. 2007;7(5):365–378. doi: 10.1038/nri2072
19. Oettgen HC. Fifty years later: Emerging functions of IgE antibodies in host defense, immune regulation, and allergic diseases. J Allergy Clin Immunol. 2016;137(6):1631–1645. doi: 10.1016/j.jaci.2016.04.009
20. Hamilton RG, MacGlashan DW Jr, Saini SS. IgE antibodyspecific activity in human allergic disease. Immunol Res. 2010; 47(1–3):273–284. doi: 10.1007/s12026-009-8160-3
21. Simons FE, Frew AJ, Ansotegui IJ, et al. Risk assessment in anaphylaxis: current and future approaches. J Allergy Clin Immunol. 2007;120(1 Suppl):S2–S24. doi: 10.1016/j.jaci.2007.05.001
22. Sicherer SH, Sampson HA. Food allergy. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S116–S125. doi: 10.1016/j.jaci.2009.08.028
23. Khodoun M, Strait R, Orekov T, et al. Peanuts can contribute to anaphylactic shock by activating complement. J Allergy Clin Immunol. 2009;123(2):342–351. doi: 10.1016/j.jaci.2008.11.004
24. Khodoun MV, Strait R, Armstrong L, et al. Identification of markers that distinguish IgE-from IgG-mediated anaphylaxis. Proc Natl Acad Sci U S A. 2011;108(30):12413–12418. doi: 10.1073/pnas.1105695108
25. Arias K, Chu DK, Flader K, et al. Distinct immune effector pathways contribute to the full expression of peanut-induced anaphylactic reactions in mice. J Allergy Clin Immunol. 2011;127(6):1552–1561. e1. doi: 10.1016/j.jaci.2011.03.044
26. de Silva D, Singh C, Muraro A, et al. Diagnosing, managing and preventing anaphylaxis: Systematic review. Allergy. 2021; 76(5):1493–1506. doi: 10.1111/all.14580
27. Cardona V, Ansotegui IJ, Ebisawa M, et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J. 2020;13(10):100472. doi: 10.1016/j.waojou.2020.100472
28. Ilyina NI, Zabolotskikh IB, Astafieva NG, et al. Anaphylactic shock. Clinical guidelines of Russian Association of Allergists and Clinical Immunologists and the All-Russian Public Organization “Federation of Anesthesiologists and Reanimatologists”. Annals of Critical Care. 2020;(3):15–26. (In Russ). doi: 10.21320/1818-474X-2020-3-15-26
29. Allergologiya i immunologiya. Namazova-Baranova LS, Baranov AA, Khaitov RM, eds. Moscow: Union of Pediatricians of Russia; 2020. (In Russ).
30. Lieberman P, Nicklas R, Oppenheimer J, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 Update. J Allergy Clin Immunol. 2010;126(3):477–480.e42. doi: 10.1016/j.jaci.2010.06.022
31. Sala-Cunill V. Cardona Biomarkers of anaphylaxis, beyond tryptase. Curr Opin Allergy Clin Immunol. 2015;15(4):329–336. doi: 10.1097/ACI.0000000000000184
32. Serrano CD, Gomez JF. Successful desensitization to idursulfase in a patient with type II mucopolysaccharidosis (Hunter syndrome). J Investig Allergol Clin Immunol. 2011;21(7):571–572.
33. Kruchina TK, Bruchikov KV, Novik GA. Experience of Idursulfase Beta Administration in the Child with Mucopolysaccharidosis Type II: Clinical Case. Voprosy sovremennoi pediatrii — Current Pediatrics. 2020;19(5):364–370. (In Russ). doi: 10.15690/vsp.v19i5.2212
34. Reber LL, Hernandez JD, Galli SJ. The pathophysiology of anaphylaxis. J Allergy Clin Immunol. 2017;140(2):335–348. doi: 10.1016/j.jaci.2017.06.003
35. Matheu V, Franco A, Pérez E, et al. Omalizumab for drug allergy. J Allergy Clin Immunol. 2007;120(6):1471–1472; author reply 1472–1473. doi: 10.1016/j.jaci.2007.07.03
36. Mishra S, Connors L, Tugwell B. Role of omalizumab in insulin hypersensitivity: a case report and review of the literature. Diabet Med. 2018;35(5):663–666. doi: 10.1111/dme.13591
37. Cavelti-Weder C, Muggli B, Keller C, et al. Successful use of omalizumab in an inadequately controlled type 2 diabetic patient with severe insulin allergy. Diabetes Care. 2012;(6):e41. doi: 10.2337/dc12-0115
38. Arroabarren E, Aznal E, Anda M, Sánchez-Valverde F. Anaphylaxis after Elosulfase A infusion: Omalizumab as coadyuvant for enzyme replacement therapy desensitization. Pediatr Allergy Immunol. 2019;30(4):491–494. doi: 10.1111/pai.13049
Review
For citations:
Levina J.G., Vashakmadze N.D., Namazova-Baranova L.S., Vishneva E.A., Zhurkova N.V., Efendieva K.E., Alekseeva A.A., Kalugina V.G. Allergic Reactions at Enzyme Replacement Therapy in Children with Mucopolysaccharidosis Type II. Current Pediatrics. 2021;20(6s):624-629. (In Russ.) https://doi.org/10.15690/vsp.v20i6S.2372
Views:
508
Email this article 
